Dysregulation of Betaglycan Expression in Primary Human Endometrial Carcinomas

REFERENCES

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun, M.J. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225–249.
   PubMed Web of Science ®Google Scholar
• Boyle P, Levin, B. World cancer report 2008. Lyon: IARC, 2008.
   Google Scholar
• Wojciechowska U, Didkowska J, Zatonski, W. Cancer in Poland in 2006. Warsaw: The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 2008.
   Google Scholar
• Padua D, Massague, J. Roles of TGFβ in metastasis. Cell Res 2009;19(1):89–102.
   PubMed Web of Science ®Google Scholar
• Massague, J. TGF-β in cancer. Cell 2008;134(2):215–230.
   PubMed Web of Science ®Google Scholar
• Massague J, Gomis, R.R. The logic of TGF-β signaling. FEBS Lett 2006;580(12):2811–2820.
   PubMed Web of Science ®Google Scholar
• Chin D, Boyle GM, Parsons PG, Coman, W.B. What is transforming growth factor-beta (TGF-β)? Br J Plast Surg 2004;57(3): 215–221.
   PubMedGoogle Scholar
• Dennler S, Goumans MJ, ten Dijke, P. Transforming growth factor β signal transduction. J Leukoc Biol 2002;71(5):731–740.
   PubMed Web of Science ®Google Scholar
• Yue J, Mulder, K.M. Transforming growth factor-β signal transduction in epithelial cells. Pharmacol Ther 2001;91(1):1–34.
   PubMed Web of Science ®Google Scholar
• de Caestecker, M. The transforming growth factor-β superfamily of receptors. Cytokine Growth Factor Rev 2004;15(1):1–11.
   PubMed Web of Science ®Google Scholar
• ten Dijke, P., Hill, C.S. New insights into TGF-β-Smad signalling. Trends Biochem Sci 2004;29(5):265–273.
   PubMed Web of Science ®Google Scholar
• Govinden R, Bhoola, K.D. Genealogy, expression, and cellular function of transforming growth factor-β. Pharmacol Ther 2003;98(2):257–265.
   PubMed Web of Science ®Google Scholar
• Derynck R, Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425(6958): 577–584.
   PubMed Web of Science ®Google Scholar
• Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono, K. Two major Smad pathways in TGF-β superfamily signalling. Genes Cells 2002;7(12):1191–1204.
   PubMed Web of Science ®Google Scholar
• Mythreye K, Blobe, G.C. The type III TGF-β receptor regulates epithelial and cancer cell migration through β-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci U S A 2009;106(20):8221–8226.
   PubMed Web of Science ®Google Scholar
• Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S, Bizet AA, Philip, A. Identification of CD109 as part of the TGF-β receptor system in human keratinocytes. FASEB J 2006;20(9):E780–E795.
   Google Scholar
• Kirkbride KC, Ray BN, Blobe, G.C. Cell-surface co-receptors: emerging roles in signaling and human disease. Trends Biochem Sci 2005;30(11):611–621.
   PubMed Web of Science ®Google Scholar
• Lebrin F, Deckers M, Bertolino P, ten Dijke, P. TGF-β receptor function in the endothelium. Cardiovasc Res 2005;65(3):599–608.
   PubMed Web of Science ®Google Scholar
• Cheifetz S, Andres JL, Massague, J. The transforming growth factor-β receptor type III is a membrane proteoglycan. Domain structure of the receptor. J Biol Chem 1988;263(32):16984–16991.
   PubMed Web of Science ®Google Scholar
• Bernabeu C, Lopez-Novoa, J.M., Quintanilla, M. The emerging role of TGF-β superfamily coreceptors in cancer. Biochim Biophys Acta 2009;1792(10):954–973.
   PubMed Web of Science ®Google Scholar
• Santander C, Brandan, E. Betaglycan induces TGF-β signaling in a ligand-independent manner, through activation of the p38 pathway. Cell Signal 2006;18(9):1482–1491.
   PubMed Web of Science ®Google Scholar
• Eickelberg O, Centrella M, Reiss M, Kashgarian M, Wells, R.G. Betaglycan inhibits TGF-β signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem 2002;277(1):823–829.
   PubMed Web of Science ®Google Scholar
• You HJ, How T, Blobe, G.C. The type III transforming growth factor-β receptor negatively regulates nuclear factor kappa B signaling through its interaction with β-arrestin2. Carcinogenesis 2009;30(8):1281–1287.
   PubMed Web of Science ®Google Scholar
• Finger EC, Lee NY, You HJ, Blobe, G.C. Endocytosis of the type III transforming growth factor-β (TGF-β) receptor through the clathrin-independent/lipid raft pathway regulates TGF-β signaling and receptor down-regulation. J Biol Chem 2008;283(50):34808–34818.
   PubMed Web of Science ®Google Scholar
• Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang XF, Lefkowitz RJ, Blobe, G.C. β-arrestin 2 mediates endocytosis of type III TGF-β receptor and down-regulation of its signaling. Science 2003;301(5638):1394–1397.
   PubMed Web of Science ®Google Scholar
• Gordon KJ, Blobe, G.C. Role of transforming growth factor-β superfamily signaling pathways in human disease. Biochim Biophys Acta 2008;1782(4):197–228.
   PubMed Web of Science ®Google Scholar
• Blobe GC, Schiemann WP, Lodish, H.F. Role of transforming growth factor β in human disease. N Engl J Med 2000;342(18): 1350–1358.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Landstrom M, Moustakas, A. Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009;21(2):166–176.
   PubMed Web of Science ®Google Scholar
• Xu J, Lamouille S, Derynck, R. TGF-β-induced epithelial to mesenchymal transition. Cell Res 2009;19(2):156–172.
   PubMed Web of Science ®Google Scholar
• Pardali K, Moustakas, A. Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007;1775(1):21–62.
   PubMed Web of Science ®Google Scholar
• Stover DG, Bierie B, Moses, H.L. A delicate balance: TGF-β and the tumor microenvironment. J Cell Biochem 2007;101(4): 851–861.
   PubMed Web of Science ®Google Scholar
• Bierie B, Moses, H.L. TGF-β and cancer. Cytokine Growth Factor Rev 2006;17(1–2):29–40.
   PubMed Web of Science ®Google Scholar
• Elliott RL, Blobe, G.C. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005;23(9):2078–2093.
   PubMed Web of Science ®Google Scholar
• Akhurst RJ, Derynck, R. TGF-β signaling in cancer: a double-edged sword. Trends Cell Biol 2001;11(11):S44–S51.
   PubMed Web of Science ®Google Scholar
• Derynck R, Akhurst RJ, Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29(2): 117–129.
   PubMed Web of Science ®Google Scholar
• Wieser, R. The transforming growth factor-β signaling pathway in tumorigenesis. Curr Opin Oncol 2001;13(1):70–77.
   PubMed Web of Science ®Google Scholar
• de Caestecker, M.P., Piek E, Roberts, A.B. Role of transforming growth factor-β signaling in cancer. J Natl Cancer Inst 2000;92(17):1388–1402.
   PubMed Web of Science ®Google Scholar
• Massague J, Blain SW, Lo, R.S. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000;103(2):295–309.
   PubMed Web of Science ®Google Scholar
• Piestrzeniewicz-Ulanska, D., Brys M, Semczuk A, Rechberger T, Jakowicki JA, Krajewska, W.M. TGF-β signaling is disrupted in endometrioid-type endometrial carcinomas. Gynecol Oncol 2004;95(1):173–180.
   PubMed Web of Science ®Google Scholar
• Piestrzeniewicz-Ulanska, D., Brys M, Semczuk A, Jakowicki JA, Krajewska, W.M. Expression and intracellular localization of Smad proteins in human endometrial cancer. Oncol Rep 2003;10(5):1539–1544.
   PubMed Web of Science ®Google Scholar
• Piestrzeniewicz-Ulanska, D., Brys M, Semczuk A, Jakowicki JA, Krajewska, W.M. Expression of TGF-β type I and II receptors in normal and cancerous human endometrium. Cancer Lett 2002;186(2):231–239.
   PubMed Web of Science ®Google Scholar
• Parekh TV, Gama P, Wen X, Demopoulos R, Munger JS, Carcangiu ML, Reiss M, Gold, L.I. Transforming growth factor β signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. Cancer Res 2002;62(10):2778–2790.
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162(1):156–159.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall, R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193(1):265–275.
   PubMed Web of Science ®Google Scholar
• Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227(5259), 680–685.
   PubMed Web of Science ®Google Scholar
• Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul-Chantler, S., Grail D, Small C, Weinberg RA, Sizeland AM, Zhu, H.J. Heart and liver defects and reduced transforming growth factor β2 sensitivity in transforming growth factor β type III receptor-deficient embryos. Mol Cell Biol 2003;23(12):4371–4385.
   PubMed Web of Science ®Google Scholar
• Blobe GC, Schiemann WP, Pepin MC, Beauchemin M, Moustakas A, Lodish HF, O'Connor-McCourt, M.D. Functional roles for the cytoplasmic domain of the type III transforming growth factor β receptor in regulating transforming growth factor beta signaling. J Biol Chem 2001;276(27):24627–24637.
   PubMed Web of Science ®Google Scholar
• Bae HJ, Eun JW, Noh JH, Kim JK, Jung KH, Xie HJ, Park WS, Lee JY, Nam, S.W. Down-regulation of transforming growth factor β receptor type III in hepatocellular carcinoma is not directly associated with genetic alterations or loss of heterozygosity. Oncol Rep 2009;22(3):475–480.
   PubMed Web of Science ®Google Scholar
• Bilandzic M, Chu S, Farnworth PG, Harrison C, Nicholls P, Wang Y, Escalona RM, Fuller PJ, Findlay JK, Stenvers, K.L. Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. Mol Endocrinol 2009;23(4):539–548.
   PubMed Web of Science ®Google Scholar
• Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe, G.C. TβRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 2008;29(3):528–535.
   PubMed Web of Science ®Google Scholar
• Gordon KJ, Dong M, Chislock EM, Fields TA, Blobe, G.C. Loss of type III transforming growth factor β receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis 2008;29(2):252–262.
   PubMed Web of Science ®Google Scholar
• Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H, LeGrand SN, Tamboli P, Wood, C.G. Genomic profiling identifies alterations in TGFβ signaling through loss of TGFβ receptor expression in human renal cell carcinogenesis and progression. Oncogene 2003;22(39):8053–8062.
   PubMed Web of Science ®Google Scholar
• Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe, G.C. The type III TGF-β receptor suppresses breast cancer progression. J Clin Invest 2007;117(1):206–217.
   PubMed Web of Science ®Google Scholar
• Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe, G.C. Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Res 2007;67(11):5231–5238.
   PubMed Web of Science ®Google Scholar
• Sharifi N, Hurt EM, Kawasaki BT, Farrar, W.L. TGFBR3 loss and consequences in prostate cancer. Prostate 2007;67(3):301–311.
   PubMed Web of Science ®Google Scholar
• Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe, G.C. The type III transforming growth factor-β receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 2007;67(3):1090–1098.
   PubMed Web of Science ®Google Scholar
• Iolascon A, Giordani L, Borriello A, Carbone R, Izzo A, Tonini GP, Gambini C, Della Ragione, F. Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas. Br J Cancer 2000;82(6):1171–1176.
   PubMed Web of Science ®Google Scholar
• Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, Shah N, Kay, N.E. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 2003;1(5):346–361.
   PubMed Web of Science ®Google Scholar
• Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, Neri A, Califano A, Dalla-Favera, R. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194(1):1625–1638.
   PubMedGoogle Scholar
• Lee JD, Hempel N, Lee NY, Blobe, G.C. The type III TGF-β receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-β signaling. Carcinogenesis 2010;31(2):175–183.
   PubMed Web of Science ®Google Scholar
• Blobe GC, Liu X, Fang SJ, How T, Lodish, H.F. A novel mechanism for regulating transforming growth factor β (TGF-β) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J Biol Chem 2001;276(43):39608–39617.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Wang L, Lopez-Casillas, F., Mendoza V, Yeh IT, Sun, L. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate 2005;63(1):81–90.
   PubMed Web of Science ®Google Scholar
• Criswell TL, Dumont N, Barnett JV, Arteaga, C.L. Knockdown of the transforming growth factor-β type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res 2008;68(18):7304–7312.
   PubMed Web of Science ®Google Scholar
• Florio P, Ciarmela P, Reis FM, Toti P, Galleri L, Santopietro R, Tiso E, Tosi P, Petraglia, F. Inhibin α-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma. Eur J Endocrinol 2005;152(2):277–284.
   PubMed Web of Science ®Google Scholar